Esophageal Squamous Cell Carcinoma Clinical Trial
Official title:
A Case-Control Study of Esophageal Squamous Cell Carcinoma in Lilongwe, Malawi
Background:
Esophageal cancer is a common cause of cancer deaths. Most cases of this cancer are
esophageal squamous cell carcinoma (ESCC). Many of these cases come from two parts of the
world with high-risk. One of these is in East Africa and include the country of Malawi.
Researchers want to learn what factors explain the high risk there so we can understand
better what causes this cancer in people everywhere.
Objective:
To learn more about causes and outcomes of esophageal squamous cell carcinoma using Malawi
because of the large number of cases in that country.
Eligibility:
Adults at least 18 years old who have ESCC and live in a certain region of Malawi
Adults in the same age group and location who do not have ESCC
Design:
Participants will be screened at a hospital in Malawi.
Participants will have a 1-hour interview. They will answer questions about:
Demographics (age, ethnicity, education)
Place of residence
Medical history and family medical history
Drug, alcohol, and tobacco use
Hot beverage consumption
Indoor air pollution
Occupation
Food habits
Farming
Gastrointestinal health
Participants will have their teeth and fingernails examined.
Participants will be asked to give samples of blood, urine, saliva, toenails, and for the
cancer cases, a small piece of their tumor.
Participants will have 4 phone calls a year for 2 years to ask about their health....
Background: Esophageal cancer causes an estimated 400,000 deaths per year and ranks as the
sixth leading cause of cancer death worldwide, just after breast cancer. Esophageal squamous
cell carcinoma (ESCC) accounts for 89% of all esophageal cancer cases worldwide and many of
the cases originate in two high risk regions, one in Asia and the other in Africa.
Smoking tobacco and heavy alcohol consumption do not explain the incidence rates in the
high-risk regions. It is therefore important to consider a wide range of etiologic factors to
explain the high rates of cancer in these populations.
Malawi has the highest incidence rates of ESCC in Africa. Our previous studies in Kenya and
preliminary studies in Malawi point to a number of potential ESCC risk factors.
Objectives: Our study aims to enhance our understanding of the causes and outcomes for ESCC
in Malawi
Eligibility: All suspected ESCC cases will be eligible for enrollment.
Design: We will conduct a case-control study of ESCC jointly at Kamuzu Central Hospital and
St. Gabriel s Hospital, recruiting 300 ESCC cases and 300 controls, to (1) evaluate exposures
(including consumption of very hot beverages, use of firewood as fuel, tooth loss and animal
exposure) which may influence risk of ESCC in Malawi and (2) collect biological samples to
quantify exposures of interest (included in the current proposal) and to study the genetics
and genomics of ESCC tumors (to be included in a future proposal).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06056336 -
Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma
|
Phase 2 | |
Suspended |
NCT04084158 -
A Study of Toripalimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.
|
Phase 2 | |
Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT05561699 -
Sequential Preoperative Penpulimab Combined With Chemoradiotherapy(CRT) for Locally Advanced Esophageal Squamous Cell Cancer
|
N/A | |
Active, not recruiting |
NCT04543617 -
A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
|
Phase 3 | |
Recruiting |
NCT06190782 -
Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor
|
Phase 3 | |
Completed |
NCT05557955 -
Identification of Breath Biomarkers in Esophageal Cancer
|
||
Recruiting |
NCT04045496 -
A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04584008 -
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
|
N/A | |
Not yet recruiting |
NCT03766178 -
Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
|
Phase 2 | |
Recruiting |
NCT02913066 -
S-1 IMRT Versus S-1 and Cisplatin Concurrent IMRT in Inoperable Esophageal Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT02399306 -
Chemoradiotherapy With or Without Enteral Nutrition for Locally Advanced Thoracic Esophageal Carcinoma
|
Phase 3 | |
Completed |
NCT01605305 -
Study on FOLFOX6 as First-line Therapy to Treat Recurrent or Metastatic Esophageal Cancer
|
Phase 2 | |
Not yet recruiting |
NCT05552651 -
Envafolimab Combined With Chemotherapy in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma
|
Phase 2 | |
Recruiting |
NCT05520619 -
Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002)
|
Phase 2 | |
Terminated |
NCT03251417 -
Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal Squamous Cell Carcinoma
|
Phase 2 | |
Recruiting |
NCT05990231 -
Cadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined With Platinum-containing Chemotherapy
|
Phase 2 | |
Recruiting |
NCT04644250 -
Combination of Toripalimab and Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT02916511 -
Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy Concurrent With Chemotherapy for Esophageal Squamous Cell Carcinoma
|
Phase 2 | |
Terminated |
NCT04032704 -
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
|
Phase 2 |